
    
      Phase I Study

        -  to determine and compare the safety of single ascending doses of POL6326 by intravenous
           infusion

        -  to determine the relationship between 2-hour single intravenous infusion doses of
           POL6326 and the concentration of HSC and mature WBC in peripheral blood using
           immunophenotypic assays.
    
  